首页> 外文期刊>Diabetes >C. elegans as Model for the Study of High Glucose- Mediated Life Span Reduction
【24h】

C. elegans as Model for the Study of High Glucose- Mediated Life Span Reduction

机译:秀丽隐杆线虫作为高糖介导的寿命减少研究的模型

获取原文
获取原文并翻译 | 示例
       

摘要

Objective-Establishing Caenorhabditis elegans as a model for glucose toxicity-mediated life span reduction.rnResearch design and methods-C. elegans were maintained to achieve glucose concentrations resembling the hyperglycemic conditions in diabetic patients. The effects of high glucose on life span, glyoxalase-1 activity, advanced glyeation end products (AGEs), and reactive oxygen species (ROS) formation and on mitochondrial function were studied.rnResults-High glucose conditions reduced mean life span from 18.5 ± 0.4 to 16.5 ± 0.6 days and maximum life span from 25.9 ± 0.4 to 23.2 ± 0.4 days, independent of glucose effects on cuticle or bacterial metabolization of glucose. The formation of methylglyoxal-modified mitochondrial proteins and ROS was significantly increased by high glucose conditions and reduced by mitochondrial uncoupling and complex IIIQo inhibition. Over-expression of the methylglyoxal- detoxifying enzyme glyoxalase-1 attenuated the life-shortening effect of glucose by reducing AGE accumulation (by 65%) and ROS formation (by 50%) and restored mean (16.5 ± 0.6 to 20.6 ± 0.4 days) and maximum life span (23.2 ± 0.4 to 27.7 ± 2.3 days). In contrast, inhibition of glyoxalase-1 by RNAi further reduced mean (16.5 ± 0.6 to 13.9 ± 0.7 days) and maximum life span (23.2 ± 0.4 to 20.3 ± 1.1 days). The life span reduction by glyoxalase-1 inhibition was independent from the insulin signaling pathway because high glucose conditions also affected daf-2 knockdown animals in a similar manner.rnConclusions-C. elegans is a suitable model organism to study glucose toxicity, in which high glucose conditions limit the life span by increasing ROS formation and AGE modification of mitochondrial proteins in a daf-2 independent manner. Most importantly, glucose toxicity can be prevented by improving glyoxalase-1-dependent methylglyoxal detoxification or preventing mitochondrial dysfunction.
机译:目的建立秀丽隐杆线虫作为降低葡萄糖毒性介导的寿命的模型。研究设计和方法。维持线虫达到类似于糖尿病患者的高血糖状况的葡萄糖浓度。研究了高糖对寿命,乙二醛酶1活性,高级胶凝终产物(AGEs)和活性氧(ROS)的形成以及线粒体功能的影响。rn结果-高糖条件使平均寿命从18.5±0.4降低至16.5±0.6天,最大寿命从25.9±0.4至23.2±0.4天,不受葡萄糖对表皮或葡萄糖细菌代谢的影响。高糖条件显着增加了甲基乙二醛修饰的线粒体蛋白质和ROS的形成,而线粒体解偶联和复杂的IIIQo抑制则减少了这些形成。甲基乙二醛解毒酶乙二醛酶1的过表达通过减少AGE积累(减少65%)和ROS形成(减少50%)并恢复平均值(16.5±0.6至20.6±0.4天)来减弱葡萄糖的寿命缩短作用最长寿命(23.2±0.4至27.7±2.3天)。相比之下,RNAi对乙二醛酶1的抑制作用进一步降低了平均值(16.5±0.6至13.9±0.7天)和最大寿命(23.2±0.4至20.3±1.1天)。乙二醛酶-1抑制的寿命减少独立于胰岛素信号传导途径,因为高葡萄糖条件也以类似方式影响daf-2敲低动物。线虫是研究葡萄糖毒性的合适模型生物,其中高葡萄糖条件通过以daf-2独立的方式增加ROS的形成和线粒体蛋白的AGE修饰来限制寿命。最重要的是,可以通过改善乙二醛酶1依赖性甲基乙二醛解毒或预防线粒体功能障碍来预防葡萄糖毒性。

著录项

  • 来源
    《Diabetes》 |2009年第11期|2450-2456|共7页
  • 作者单位

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Simon Fraser University, Department of Biological Sciences, Burnaby, Canada;

    Departments of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, New York;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Warwick Medical School, Clinical Sciences Research Institute, University of Warwick, University Hospital, Coventry, U.K.;

    Warwick Medical School, Clinical Sciences Research Institute, University of Warwick, University Hospital, Coventry, U.K.;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany Diabetes-Clinic, Center for Vascular Medicine, Bad Nauheim, Germany;

    College of Medicine, University of Cincinnati, Cincinnati, Ohio;

    Departments of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, New York;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

    Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:44

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号